SGC-CBP30: Selective CREBBP/EP300 Bromodomain Inhibition

Executive Summary: SGC-CBP30 is a small-molecule inhibitor designed for selective modulation of the CREBBP and EP300 bromodomains, with IC₅₀ values of 21 nM and 38 nM, respectively, as reported in the APExBIO product documentation. This compound is used to interrogate transcriptional coactivator function and chromatin regulation, especially in the context of cancer epigenetics. Its role is particularly relevant for dissecting super-enhancer hijacking and TGF-β/SMAD3 pathway modulation in lung adenocarcinoma, as illustrated by recent research (Zhang et al., 2022). SGC-CBP30 demonstrates reliable solubility and stability under controlled laboratory conditions. APExBIO supplies SGC-CBP30 for research applications in chromatin biology, transcriptional regulation, and cancer biology.

Biological Rationale

CREBBP (CREB-binding protein) and EP300 (E1A binding protein p300) are transcriptional coactivators with intrinsic histone acetyltransferase activity. They modulate gene expression by interacting with diverse transcription factors and regulating chromatin accessibility through their bromodomains. Aberrant CREBBP/EP300 activity has been implicated in tumorigenesis, particularly through epigenetic dysregulation in cancers such as lung adenocarcinoma. Super-enhancer regions, which are large genomic domains enriched for transcriptional activation, recruit CREBBP/EP300 and facilitate oncogenic transcriptional programs. The reference study by Zhang et al. (2022) demonstrates that super-enhancer hijacking of LINC01977 drives malignancy in early-stage lung adenocarcinoma via the canonical TGF-β/SMAD3 pathway, with CREBBP/EP300 as essential coactivators.

Mechanism of Action of SGC-CBP30

SGC-CBP30 is a small molecule that selectively binds to the bromodomains of CREBBP and EP300, preventing their interaction with acetylated histone tails. This inhibition disrupts the assembly of transcriptional complexes at enhancer and promoter regions, impeding the transcription of target genes. By modulating CREBBP/EP300 activity, SGC-CBP30 enables researchers to dissect the contribution of specific coactivator-driven epigenetic events, such as enhancer reprogramming and the activation of oncogenic noncoding RNAs like LINC01977. The specificity of SGC-CBP30 for CREBBP (IC₅₀ = 21 nM) and EP300 (IC₅₀ = 38 nM) is reported in the APExBIO technical documentation and validated in cell-based assays.

Evidence & Benchmarks

• SGC-CBP30 exhibits potent inhibition of CREBBP and EP300 bromodomains with nanomolar IC₅₀ values (21 nM and 38 nM, respectively), as reported in the product datasheet.
• In HeLa cells, SGC-CBP30 reduces FRAP recovery times in SAHA-treated conditions, indicating modulation of chromatin dynamics (APExBIO).
• SGC-CBP30 inhibits doxorubicin-induced p53 activity in RKO cells in a dose-dependent manner, demonstrating functional impact on transcriptional coactivator-mediated gene expression (APExBIO).
• In the context of lung adenocarcinoma, CREBBP/EP300 are shown to facilitate the interaction between SMAD3 and super-enhancer-hijacked LINC01977, driving malignancy via TGF-β/SMAD3 signaling (Zhang et al., 2022).
• Super-enhancer activity and CREBBP/EP300 recruitment are linked to poor prognosis in early-stage LUAD, highlighting the translational relevance of selective bromodomain inhibition (Zhang et al., 2022).

This article extends prior coverage such as "SGC-CBP30: Unlocking Selective Bromodomain Inhibition for..." by integrating the latest mechanistic insights from super-enhancer hijacking studies, and clarifies specific use cases highlighted in "Disrupting Super-Enhancer Hijacking in Early-Stage Lung Adenocarcinoma" by providing updated protocol guidance and evidence benchmarks.

Applications, Limits & Misconceptions

SGC-CBP30 is widely used in epigenetics research, cancer biology, and studies of transcriptional coactivator inhibition. Researchers deploy it to probe enhancer reprogramming, chromatin accessibility, and gene regulation in both normal and disease contexts, including early-stage lung adenocarcinoma. The compound is particularly valuable for dissecting TGF-β/SMAD3 signaling and super-enhancer-driven gene expression. However, SGC-CBP30 should not be interpreted as a therapeutic; its use is limited to research applications. Its selective action on CREBBP/EP300 bromodomains does not inhibit other bromodomain-containing proteins, and off-target effects may still occur at higher concentrations.

Common Pitfalls or Misconceptions

• SGC-CBP30 is not a pan-bromodomain inhibitor; it is selective for CREBBP and EP300.
• The compound is not suitable for in vivo therapeutic applications due to limited pharmacokinetic data.
• Long-term storage of SGC-CBP30 in solution is not recommended; stability is optimal in solid form at 4°C (APExBIO).
• Observed effects in cell lines may not directly translate to clinical settings; mechanistic studies should be interpreted with caution (Zhang et al., 2022).
• SGC-CBP30 cannot discriminate between CREBBP and EP300 bromodomains; both are inhibited with high affinity.

Workflow Integration & Parameters

SGC-CBP30 (SKU: A4491) from APExBIO is available as a solid reagent for research use. The recommended workflow includes dissolution, storage, and assay integration steps, with attention to solubility and stability parameters.

Protocol Parameters

• Solubility in DMSO: ≥20.05 mg/mL; dissolve with gentle agitation for complete solubilization (APExBIO).
• Solubility in ethanol: ≥25.7 mg/mL with ultrasonic assistance; ensure full dissolution before dilution.
• Solubility in water: ≥4.67 mg/mL with ultrasonic assistance; recommended for aqueous applications only.
• Storage (solid): 4°C for optimal long-term stability; avoid repeated freeze-thaw cycles (APExBIO).
• Storage (stock solution): -20°C; use within several months, do not store for extended periods.
• Cellular assay concentrations: Literature reports efficacy between 0.1–10 μM, with validation in HeLa and RKO cell lines (APExBIO).
• Workflow note: For super-enhancer and TGF-β/SMAD3 pathway studies, integrate SGC-CBP30 treatment prior to or concurrent with pathway activation, as described in Zhang et al. (2022).

Conclusion & Outlook

SGC-CBP30 is a validated, selective CREBBP/EP300 bromodomain inhibitor with robust utility in epigenetics and cancer biology research. Its nanomolar potency and well-characterized mechanism of action make it a reference tool for dissecting enhancer-mediated transcriptional control, including super-enhancer hijacking in lung adenocarcinoma. As highlighted by Zhang et al. (2022), targeting CREBBP/EP300 function offers a strategic approach to understanding and potentially modulating TGF-β/SMAD3-driven oncogenic programs. Future research may further refine selective bromodomain inhibition strategies, but SGC-CBP30 remains a benchmark compound for advanced studies in chromatin biology, transcriptional regulation, and epigenetic control.